DNA vs SCLX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

DNA

48.2
AI Score
VS
SCLX Wins

SCLX

52.0
AI Score

Investment Advisor Scores

DNA

48score
Recommendation
HOLD

SCLX

52score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric DNA SCLX Winner
Forward P/E 0 5.5772 Tie
PEG Ratio 0 0 Tie
Revenue Growth -5.7% -22.8% DNA
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 48.2/100 52.0/100 SCLX
Profit Margin -192.0% 0.0% SCLX
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

DNA 1M: -12.8% · 3M: +41.6% SCLX 1M: -43.7% · 3M: -76.0%

Current Technical Phase

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 47.1 · Price: $10.25

SCLX

Markdown
Sell / avoid

Price below a falling SMA50 (slope -31.2%), weak momentum, RSI 15

RSI (14): 15.0 · Price: $1.62

Fundamentals Snapshot

Metric DNA SCLX
Market Cap — —
Forward P/E -3.5 2.2
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.1% -0.2%
Gross Margin 0.7% 0.6%
Operating Margin -1.6% -3.9%
EPS -4.24 -49.70
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, SCLX is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.